14
Mar

FDA OKs new Novartis drug for type of advanced breast cancer

U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer.

The drug, called Kisqali and developed by Swiss drugmaker Novartis AG, is a pill that works to slow the spread of cancer by blocking two proteins that can stimulate growth and division of cancer cells.

It’s for women who have metastatic breast cancer known as HR /HER2-. About 40 percent of U.S. women diagnosed with breast cancer have this type, according to the American Cancer Society.

Read Full Article Here >>